These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

646 related items for PubMed ID: 16123563

  • 1. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S.
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [Abstract] [Full Text] [Related]

  • 2. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 3. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
    J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
    [Abstract] [Full Text] [Related]

  • 5. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 6. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, De La Taille A, Abbou CC, Chopin DK.
    J Urol; 2001 Dec; 166(6):2142-7. PubMed ID: 11696723
    [Abstract] [Full Text] [Related]

  • 7. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH.
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [Abstract] [Full Text] [Related]

  • 8. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B, Değirmenci T, Arslan M, Nergiz N, Minareci S, Ayder AR.
    Urol Int; 2005 Nov; 75(2):107-13. PubMed ID: 16123562
    [Abstract] [Full Text] [Related]

  • 9. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 10. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
    Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O'Donnell MA.
    Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF.
    N Engl J Med; 1991 Oct 24; 325(17):1205-9. PubMed ID: 1922207
    [Abstract] [Full Text] [Related]

  • 12. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V, Emiliozzi P, depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Sternberg CN.
    J Exp Clin Cancer Res; 2003 Dec 24; 22(4 Suppl):223-7. PubMed ID: 16767936
    [Abstract] [Full Text] [Related]

  • 13. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M, Urrutia M, Romani R, Herrero M, Gonzalez de Buitrago JM, Navajo JA.
    Anticancer Res; 2001 Dec 24; 21(4B):3041-7. PubMed ID: 11712808
    [Abstract] [Full Text] [Related]

  • 14. Bacillus Calmette-Guerin-refractory superficial bladder cancers: focus on pretreatment episodes.
    Okamura T, Akita H, Tozawa K, Kawai N, Nagata D, Kohri K.
    Int J Clin Oncol; 2003 Jun 24; 8(3):168-73. PubMed ID: 12851841
    [Abstract] [Full Text] [Related]

  • 15. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr 24; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 16. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG, Gschwend JE, Maier SH, Seidl-Schlick EM, Bach D, Romics I.
    J Urol; 2003 Mar 24; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [Abstract] [Full Text] [Related]

  • 17. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V, Pode D, Pikarsky E, Mandelboim O.
    J Urol; 2007 Dec 24; 178(6):2660-4. PubMed ID: 17945285
    [Abstract] [Full Text] [Related]

  • 18. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T, Alter A, Wiechno P.
    Urol Int; 2008 Dec 24; 80(1):74-9. PubMed ID: 18204238
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2009 Mar 24; 16(3):279-86. PubMed ID: 19207609
    [Abstract] [Full Text] [Related]

  • 20. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K.
    J Urol; 1997 Feb 24; 157(2):492-8. PubMed ID: 8996341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.